

University of Groningen

Practice research in the field of gout - clinical pharmacology of antihyperuricemic drugs

Reinders, Mattheus Karsien

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2008

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Reinders, M. K. (2008). *Practice research in the field of gout - clinical pharmacology of antihyperuricemic drugs*. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Publications related to the thesis

Chapters of this thesis

1. Moolenburgh JD, Reinders MK, Jansen TLThA. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. *Clin Rheumatol* 2006;25:749-52.
2. Reinders MK, van Roon EN, Houtman PM, Brouwers JRBJ, Jansen TLThA. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. *Clin Rheumatol* 2007;26:1459-65.
3. Jansen TLThA, Reinders MK. Jicht. In: Janssen M, Kallenberg CGM, Van Riel PLCM. *Reumatologie protocollen handboek. Een beknopte leidraad voor de praktijk*. Utrecht: Academic Pharmaceutical Productions bv, 2007. p. 113-34 [Dutch].
4. Reinders MK, Nijdam LC, van Roon EN, Movig KL, Jansen TLThA, van de Laar MAFJ, Brouwers JRBJ. A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection. *J Pharm Biomed Anal* 2007;45:312-7.
5. Reinders MK, van Roon EN, Jansen TLThA, Delsing J, Griep EN, Hoekstra M, van de Laar MAFJ, Brouwers JRBJ. Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. *Ann Rheum Dis*;doi:10.1136/ard.2007.083071. Epub ahead of print (PMID: 18250112).
6. Reinders MK, Haagsma C, Jansen TLThA, van Roon EN, Delsing J, van de Laar MAFJ, Brouwers JRBJ. A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. *Ann Rheum Dis* 2008; doi:10.1136/ard.2008.091462. Epub ahead of print (PMID: 18633127).

Other related publications

1. Jansen TL, Reinders MK, van Roon EN, Brouwers JRBJ. Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"? *Clin Exp Rheumatol* 2004;22:651.
2. Reinders MK, van Roon EN, Brouwers JRBJ, Jansen TLThA. *Beleid zonder visie doet pijn. Effectiviteit van allopurinol en benzbromaron bij gecompliceerde jicht*. *Pharm Weekbl* 2004;139:1710-3.
3. Reinders MK, van Roon EN. *NHG-Standaard Jicht, eerste herziening*. *Pharm Weekbl* 2005;140:260-2.
4. Reinders MK, van Roon EN, Brouwers JRBJ, Jansen TLThA. A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable? *Ann Rheum Dis* 2005;64:516.

5. Brouwers JRBJ, Reinders MK, van Roon EN, van de Laar MAFJ. Nieuwe inzichten in de behandeling van jicht. *Patient Care* 2006;33(7/8):21-6.
6. Reinders MK, Brouwers JRBJ, Jansen TLThA. Survey among Dutch rheumatologists on management of gout. *Ann Rheum Dis* 2008;67:1049.

Abstracts

1. Reinders MK, Van Roon EN, Brouwers JRBJ, Jansen TLThA. Benzbromarone is more potent than probenecid in reducing serum uric acid in clinical practice (OP0120). *Ann Rheum Dis* 2005;64:S95.
2. Reinders MK, van Roon EN, Houtman PM, Brouwers JRBJ, Jansen TLThA. Biochemische effectiviteit van allopurinol-probenecide bij patiënten met jicht die eerder behandeld werden met benzbromaron. *Ned Tijdschr Reum* 2006;4:S20.
3. Reinders MK, Ten Have P, Van Roon EN, Brouwers JRBJ, Jansen TLThA. Resultaten van een enquête onder reumatologen naar onderhoudsbehandeling van jicht. *Ned Tijdschr Reum* 2006;4:S21.
4. Reinders MK, van Roon EN, Houtman PM, Brouwers JRBJ, Jansen TLThA. Biochemical effectiveness of allopurinol monotherapy and allopurinol-probenecid combination therapy in previously benzbromarone-treated gout patients (P466E). 41st ASHP Midyear Clinical Meeting and Exhibition 2006.
5. Reinders MK, Van Roon EN, Jansen TLThA, Griep EN, Van de Laar MAFJ, Brouwers JRBJ. Efficacy and tolerability of allopurinol, benzbromarone and probenecid in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol (THU0350). *Ann Rheum Dis* 2007;66:S234.
6. Reinders MK, Jansen TLThA. Rasburicase for severe tophaceous gout - a case report (AB0740). *Ann Rheum Dis* 2007;66:S624.
7. Reinders MK, Van Roon EN, Houtman PM, Wilffert B, Brouwers JRBJ, Jansen TLThA. Biochemical effectiveness of allopurinol monotherapy and allopurinol-probenecid combination therapy in previously benzbromarone-treated gout patients. *Naunyn-Schmiedeberg's Archives Of Pharmacology* 2007;375:S110.
8. Reinders MK, Haagsma C, Van Roon EN, Delsing J, Jansen TLThA, Van de Laar MAFJ, Brouwers JRBJ. Dose-escalation of allopurinol versus benzbromarone in gout patients: a randomised controlled trial (OP0157). *Ann Rheum Dis* 2008;67:S98.